KLRS is Kalaris Therapeutics, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $3.90. Market cap: $93M.
Stock snapshot
| Price | $3.90 |
| Market cap | $93M |
| Sector | Healthcare |
| Exchange | NGM |
| Pays dividend | No |
About KLRS
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Related non-dividend companies
Other non-dividend stocks investors research alongside KLRS. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is KLRS's current stock price?
KLRS (Kalaris Therapeutics, Inc.) is currently trading at $3.90.
Does KLRS pay a dividend?
KLRS (Kalaris Therapeutics, Inc.) does not currently pay a regular dividend.
Track KLRS in DiviDrip
Add KLRS to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search KLRS and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-07. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.